Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy

NCT04483700 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Development program terminated

Conditions

Ankylosing Spondylitis

Interventions

DRUG: Filgotinib
DRUG: Placebo to Match Filgotinib

Sponsor

Gilead Sciences

Collaborators

[object Object]